WIGRAINE Drug Patent Profile
✉ Email this page to a colleague
When do Wigraine patents expire, and what generic alternatives are available?
Wigraine is a drug marketed by Organon Usa Inc and is included in one NDA.
The generic ingredient in WIGRAINE is caffeine; ergotamine tartrate. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the caffeine; ergotamine tartrate profile page.
Summary for WIGRAINE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 124 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | WIGRAINE at DailyMed |
Recent Clinical Trials for WIGRAINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Stanford University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for WIGRAINE
US Patents and Regulatory Information for WIGRAINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Organon Usa Inc | WIGRAINE | caffeine; ergotamine tartrate | TABLET;ORAL | 086562-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |